Gregoire Sylvie 4

What Happened Sylvie Gregoire, a 10% owner who was elected to CervoMed's board, received a derivative award on June 8, 2026: an option to purchase 8,150 shares of CervoMed common stock under the company's 2025 Equity Incentive Plan. The Form 4 reports the acquisition as type "A" (award/grant) with $0.00 listed for the immediate cash value; this reflects a grant of an option rather than a cash purchase.

Key Details

• Transaction date (period of report): June 8, 2026; Form 4 filed June 10, 2026 (timely).
• Security/amount: Option to purchase 8,150 shares (derivative award).
• Reported price: $0.00 on the Form 4 (award/grant entry; not an open-market purchase).
• Vesting: Under the grant terms, the underlying shares vest monthly in equal 1/12th increments on the last day of each month beginning June 30, 2026, subject to continued service.
• Shares owned after transaction: Not specified in the filing.
• Transaction code: A (award/grant). No mention of exercise price or immediate sale.

Context This is a standard non-employee director compensation award tied to board service, not an open-market purchase or sale. For retail investors, awards to directors are routine and generally reflect compensation policy rather than an immediate market sentiment signal. The award vests over one year and will only convert into vested shares if the director remains in service and, if exercised, any exercise price and subsequent sale would be reported in future filings.